Elan’s Drug Research Corp.
Naproxen is lead compound in DRC's IPDAS gastrointestinal protective drug absorption system development program, Elan said Nov. 16 in announcement of completion of unit rights offering in DRC. Company hopes to show that IPDAS naproxen has a better side effect profile when dosed once-daily, along with less gastric irritation and side effects. Elan hopes to commence clinicals in "very near future" in order to have product on market in 1994. Rights offering for RDC was 50% oversubscribed. Unit offering raised $43.2 mil. to develop two early stage drug delivery systems ("The Pink Sheet" Sept. 3, p. 14). Elan said early work on ETDAS electrotransport "wristwatch" system will focus on cardiovascular and anti-asthma products and narcotic analgesics.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.